Welcome to our dedicated page for International Flavors & Fragrances news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors & Fragrances stock.
International Flavors & Fragrances Inc. (IFF) is a leading innovator in creating sensorial experiences that drive the world of flavors and fragrances. Headquartered in New York, the company partners with customers globally to develop unique products for the food, beverage, health, personal care, and household goods industries. With a strong commitment to discovery and innovation, IFF continuously explores new possibilities in both fine fragrances and beauty, as well as in beloved foods and beverages.
IFF's core businesses include the Nourish segment, which accounts for nearly half of its revenue. This segment specializes in producing flavors, texturants, and plant-based proteins, providing essential ingredients that enhance the appeal and functionality of food products. Additionally, the Health & Biosciences division, generating roughly one-fourth of the company's revenue, is renowned for its expertise in probiotics and enzymes, making significant contributions to health and wellness solutions.
The company leverages its global team of 7,300 professionals along with leading consumer insights, research and development, and creative expertise to deliver differentiated products. Their proprietary formulations and custom solutions are a testament to their innovative approach and customer-centric focus.
IFF has recently made remarkable advancements in excipient technology, presenting its comprehensive range at global events such as CPhI Japan 2024 and Vitafoods Europe 2024. These showcases highlight the company's commitment to driving pharmaceutical innovation, with notable products like METHOCEL™, ETHOCEL™, and POLYOX™ under its new controlled release platform, 'Timing is Everything'. This new platform emphasizes the importance of controlled release in pharmaceutical therapies, aiming to improve patient compliance and treatment efficacy.
IFF continues to expand its innovative offerings and partnerships, demonstrating a significant impact across various industries. The company's dedication to sustainability and precision in science and creativity positions it as a key player in transforming everyday experiences and contributing to a better world.
For more detailed information about their latest projects and developments, visit their official website at iff.com.
Danisco Animal Nutrition & Health, a business unit of IFF, has received approval from the Canadian Food Inspection Agency (CFIA) for its feed solutions, Enviva® PRO and Syncra® SWI, enhancing poultry and swine production in Canada. These products aim to deliver year-round consistent animal performance. Enviva® PRO is a multi-strain microbial product enhancing feed conversion in various birds, while Syncra® SWI combines a microbial product and protease enzyme to improve digestibility in pigs. This approval allows Canadian producers to leverage the same performance benefits that U.S. counterparts have experienced.
LMR Naturals by IFF has developed a reliable methodology to calculate the carbon footprint of natural fragrance ingredients, collaborating with Carbone 4 to conduct a comprehensive Greenhouse Gas study. The study highlights that 95% of LMR's carbon footprint is attributed to Scope 3 emissions, emphasizing the need for a holistic approach to sustainability. The methodology allows customers to assess the carbon impact of their fragrance formulations, identifying high-impact ingredients and opportunities for GHG reductions through improved production processes and sustainable practices.
Philippe Horvath, a distinguished molecular biologist and technical fellow at IFF, is inducted into the National Inventors Hall of Fame® Class of 2023 for his contributions to CRISPR technology. His patents have enhanced starter cultures in the dairy industry, significantly impacting global food supply and gene editing advancements. The ceremony will take place in October 2023 in Washington, D.C. IFF expresses pride in Horvath's achievements, highlighting the importance of scientific innovation and the ongoing fight against viral infections in food fermentation.
IFF (NYSE: IFF) announced the sale of its Savory Solutions Group to PAI Partners for approximately $900 million. The deal, expected to close in Q2 2023, aims to reduce IFF's outstanding debt. The Savory Solutions Group, which generated $475 million in revenue over the past year, serves more than 11,000 customers globally. CEO Frank Clyburn highlighted the transaction as a step to enhance shareholder value and focus on higher-return businesses. The sale values the business at roughly 14 times the last 12-month EBITDA.
IFF (NYSE: IFF) has appointed Sabrya Meflah as President of its Fine Fragrance business unit, effective immediately. Meflah, previously vice president and regional general manager for EMEA, succeeds Dionisio Ferenc. Under her leadership, IFF's Fine Fragrance segment has significantly outpaced market growth. Her strategic vision has been crucial in establishing IFF as a leader in this sector, along with the launch of the Atelier du Parfumeur in Grasse, enhancing its premium market position. She holds a master’s degree in Marketing and Communication.
IFF (NYSE: IFF) announced a quarterly cash dividend of $0.81 per share, payable on January 6, 2023, to shareholders of record as of December 28, 2022. This decision reflects the company's commitment to returning value to its shareholders while reinforcing its position as a leader in the food, beverage, scent, health, and biosciences industries. IFF aims to blend artistry with science to create innovative solutions that meet global needs.
MRM Health announced that its Type-2 Diabetes Program, developed with IFF, has reached preclinical development targets. This collaboration aims to innovate therapies for metabolic diseases. Since joining forces in 2020, both companies have focused on utilizing MRM's CORAL® platform and specific IFF strains to create new therapeutics. The gut microbiome's role in Type-2 diabetes and related conditions has led to further exploration of the NAFLD program, which has shown promise in delaying disease progression.
Nicolas Mirzayantz, president of IFF's Nourish division, will leave the company after over 34 years, effective December 31, 2022. CEO Frank Clyburn will temporarily lead the Nourish division until a replacement is appointed. During his tenure, Mirzayantz held key roles, including regional manager for North America and divisional CEO of Scent, enhancing IFF’s market position through significant mergers and acquisitions. He was pivotal in integrating DuPont’s Nutrition and Biosciences unit and championed sustainability initiatives within the company.
IFF (NYSE: IFF) previews its strategic transformation and new operating model aimed at driving profitable growth and ESG+ priorities. At the Investor Day on
FAQ
What is the current stock price of International Flavors & Fragrances (IFF)?
What is the market cap of International Flavors & Fragrances (IFF)?
What does International Flavors & Fragrances Inc. (IFF) do?
What are the core business segments of IFF?
Where is IFF headquartered?
How many employees does IFF have?
What are some recent innovations by IFF?
What is the significance of the 'Timing is Everything' platform?
How does IFF support the food industry?
What role does IFF play in the health sector?
Where can I find more information about IFF's products and services?
What is IFF's approach to innovation?
